Close
Close
People News

Neuralstem Strengthens Executive Leadership Team with Appointment of Dr. David Recker as Chief Medical Officer

2.5
2.5 from 2 votes
Wednesday, November 08, 2017

Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, announced the appointment of David Recker, MD, FACR, FACP, as Chief Medical Officer.

"Given his extensive experience in the biopharma industry, Dr. Recker brings to Neuralstem an expertise that will be critical to the development of our clinical and preclinical pipeline, especially as we continue to plan our path forward," said Rich Daly, Chairman and CEO, Neuralstem. "Dr. Recker has managed execution of all elements of clinical strategy, including trial development, data interpretation and product registration. These qualifications among myriad others make him an excellent addition to our organization."

Dr. David Recker is the founding manager of JJK Consulting, a group that advises on pharmaceutical development, with an emphasis on global implementation of small molecule clinical trial design as well as a therapeutic focus on cell therapy. Dr. Recker serves as the Chief Medical Officer of Vericel Corporation, where he has been responsible for clinical development, regulatory affairs, medical and scientific affairs, pharmacovigilance, statistics and data management. Previously, Dr. Recker was Senior Vice President, Clinical Sciences with Takeda's Global Research and Development division, where he implemented global clinical development strategies for several pharmacologic agents in multiple therapeutic areas. Dr. Recker completed his M.D. with distinction at the University of Michigan Medical School.

About Neuralstem
Neuralstem is a clinical-stage biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need. NSI-189 is a small molecule in clinical development for major depressive disorder (MDD) and in preclinical development for Angelman syndrome, irradiation-induced cognitive impairment, Type 1 and Type 2 diabetes, and stroke.

NSI-566 is a stem cell therapy being tested for treatment of paralysis in stroke, chronic spinal cord injury (cSCI) and Amyotrophic Lateral Sclerosis (ALS). Neuralstem's diversified portfolio of product candidates is based on its proprietary neural stem cell technology.

Source: Neuralstem, Inc.
2.5
2.5 from 2 votes
Free Newsletter
Videos